Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease

NCT00765102 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00765102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00765102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2008
Completion date
March 1, 2010
Enrollment
32 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma